MX2023011060A - Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr). - Google Patents

Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr).

Info

Publication number
MX2023011060A
MX2023011060A MX2023011060A MX2023011060A MX2023011060A MX 2023011060 A MX2023011060 A MX 2023011060A MX 2023011060 A MX2023011060 A MX 2023011060A MX 2023011060 A MX2023011060 A MX 2023011060A MX 2023011060 A MX2023011060 A MX 2023011060A
Authority
MX
Mexico
Prior art keywords
inhibitors
ddrs
pyridine derivatives
compounds
tetrahydrothieno
Prior art date
Application number
MX2023011060A
Other languages
English (en)
Inventor
Andrea Rizzi
Laura Carzaniga
Fabio Rancati
David Edward Clark
Stefano Levanto
Nicolo Iotti
Anna Karawajczyk
Barbara Karolina Wolek
Toby Matthew Grover Mullins
Keith Christopher Knight
Ben Paul Whittaker
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2023011060A publication Critical patent/MX2023011060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula general (I) inhibidores de Receptores de Dominio Discoidina (inhibidores DDR), métodos de preparación de tales compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Los compuestos de la invención pueden ser útiles, por ejemplo, en el tratamiento de muchos trastornos asociados a mecanismos DDR.
MX2023011060A 2021-03-26 2022-03-25 Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr). MX2023011060A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21165288 2021-03-26
EP21209682 2021-11-22
PCT/EP2022/057942 WO2022200580A1 (en) 2021-03-26 2022-03-25 Tetrahydrothieno pyridine derivatives as ddrs inhibitors

Publications (1)

Publication Number Publication Date
MX2023011060A true MX2023011060A (es) 2023-09-29

Family

ID=81389152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011060A MX2023011060A (es) 2021-03-26 2022-03-25 Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr).

Country Status (13)

Country Link
EP (1) EP4313293A1 (es)
JP (1) JP2024512595A (es)
KR (1) KR20230163464A (es)
AU (1) AU2022244189A1 (es)
BR (1) BR112023019437A2 (es)
CA (1) CA3212775A1 (es)
CL (1) CL2023002821A1 (es)
CO (1) CO2023014012A2 (es)
IL (1) IL306062A (es)
MX (1) MX2023011060A (es)
PE (1) PE20240358A1 (es)
TW (1) TW202304938A (es)
WO (1) WO2022200580A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003073357A (ja) * 2001-09-03 2003-03-12 Mitsubishi Pharma Corp アミド化合物を含有するＲｈｏキナーゼ阻害剤
WO2016064970A1 (en) 2014-10-22 2016-04-28 The Board Of Regents Of The University Of Texas System Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
CN108558848A (zh) * 2018-04-19 2018-09-21 华东师范大学 一种环烷烃并噻吩衍生物及其制备方法和医药用途

Also Published As

Publication number Publication date
CL2023002821A1 (es) 2024-03-22
IL306062A (en) 2023-11-01
AU2022244189A1 (en) 2023-11-09
EP4313293A1 (en) 2024-02-07
JP2024512595A (ja) 2024-03-19
CO2023014012A2 (es) 2024-03-07
BR112023019437A2 (pt) 2023-10-24
WO2022200580A1 (en) 2022-09-29
TW202304938A (zh) 2023-02-01
KR20230163464A (ko) 2023-11-30
PE20240358A1 (es) 2024-02-27
CA3212775A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
GEP20156285B (en) Compounds and compositions as trk inhibitors
NZ714710A (en) Phosphatidylinositol 3-kinase inhibitors
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
UA106082C2 (uk) АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2023011060A (es) Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr).
MX2023011058A (es) Derivados de tetrahidrotieno piridina como inhibidores de los receptores del dominio de discoidina (ddr).